Physician profile
Bert M Bieler
NPI 1659361079
$1,814.87
in general payments reported to CMS, 2019-2025
20 companies · $231 in 2025
The $231 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $303 · 2021: $83.67 · 2022: $31.12 · 2023: $429 · 2024: $361 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $610.09 | 2019-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $225.31 | 2019-2024 | Rybelsus, Ozempic |
| Insulet Corporation | $142.82 | 2019-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $132.21 | 2020-2023 | |
| Valeritas, INC. | $125.00 | 2019 | |
| Corcept Therapeutics | $82.50 | 2019-2020 | |
| Lilly USA, LLC | $71.46 | 2019-2025 | Mounjaro, Zepbound |
| Ascendis Pharma Endocrinology INC | $62.03 | 2025 | Yorvipath |
| Medtronic, INC. | $61.08 | 2024-2025 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.92 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $40.32 | 2020-2021 | |
| Dexcom, INC. | $38.29 | 2023 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $38.23 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $36.00 | 2025 | Tarpeyo |
| Tandem Diabetes Care, INC. | $24.32 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $17.42 | 2021 | |
| Amgen INC. | $14.95 | 2023 | Repatha |
| Merck Sharp & Dohme LLC | $13.11 | 2019 | |
| Lifescan, INC. | $12.89 | 2021 | |
| Amarin Pharma, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bert Bieler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.